Measles elimination:: progress and challenges

被引:67
作者
Cutts, FT
Henao-Restrepo, AM
Olivé, JM
机构
[1] Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England
[2] WHO, Div Vaccines & Other Biol, CH-1211 Geneva, Switzerland
关键词
D O I
10.1016/S0264-410X(99)00309-6
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The accelerating progress in reducing measles incidence and mortality in many parts of the world has led to calls for its global eradication during the next 10-15 years. Three regions have established goals of elimination of indigenous transmission of measles. The strategy used in the Americas of a mass 'catchup' campaign of children 9 months to 15 years of age, high coverage through routine vaccination of infants, intensive surveillance and follow-up campaigns to prevent excessive build-up of susceptibles has had great success in reducing measles transmission close to zero. However, while these developments are impressive, much remains to be done to reduce measles-associated mortality in western and central Africa, where less than half of children are currently receiving measles vaccine and half a million children die from measles each year. The obstacles to global measles eradication are perceived to be predominantly political and financial. There are also technical questions, however. These include the refinement of measles elimination strategies in the light of recent outbreaks in the Americas; the implications of the HIV epidemic for measles elimination, issues around injection safety, and concerns about the possibility that secondary vaccine failures will contribute in sustaining transmission in highly vaccinated populations. The global priorities are to improve measles control in low income countries, increase awareness among industrialized countries of the importance of measles, and conduct studies to answer the technical questions about measles elimination strategies. (C) 1999 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:S47 / S52
页数:6
相关论文
共 55 条
[1]  
ALATTAR I, 1995, PEDIATR INFECT DIS J, V14, P149, DOI 10.1097/00006454-199502000-00013
[2]  
[Anonymous], 1992, Wkly Epidemiol Rec, V67, P357
[3]  
[Anonymous], EPI NEWSL
[4]  
Arpadi SM, 1996, PEDIATRICS, V97, P653
[5]   PREDICTING THE IMPACT OF MEASLES VACCINATION IN ENGLAND AND WALES - MODEL VALIDATION AND ANALYSIS OF POLICY OPTIONS [J].
BABAD, HR ;
NOKES, DJ ;
GAY, NJ ;
MILLER, E ;
MORGANCAPNER, P ;
ANDERSON, RM .
EPIDEMIOLOGY AND INFECTION, 1995, 114 (02) :319-344
[6]  
BIN D, 1991, B WORLD HEALTH ORGAN, V69, P415
[7]   SWEDISH EXPERIENCE OF 2 DOSE VACCINATION PROGRAM AIMING AT ELIMINATING MEASLES, MUMPS, AND RUBELLA [J].
BOTTIGER, M ;
CHRISTENSON, B ;
ROMANUS, V ;
TARANGER, J ;
STRANDELL, A .
BRITISH MEDICAL JOURNAL, 1987, 295 (6608) :1264-1267
[8]  
*CDCP, 1996, MMWR-MORBID MORTAL W, V45, P603
[9]   MEASLES ANTIBODY - REEVALUATION OF PROTECTIVE TITERS [J].
CHEN, RT ;
MARKOWITZ, LE ;
ALBRECHT, P ;
STEWART, JA ;
MOFENSON, LM ;
PREBLUD, SR ;
ORENSTEIN, WA .
JOURNAL OF INFECTIOUS DISEASES, 1990, 162 (05) :1036-1042
[10]   MEASLES-VACCINE FAILURES - LACK OF SUSTAINED MEASLES-SPECIFIC IMMUNOGLOBULIN-G RESPONSES IN REVACCINATED ADOLESCENTS AND YOUNG-ADULTS [J].
COHN, ML ;
ROBINSON, ED ;
FAERBER, M ;
THOMAS, D ;
GEYER, S ;
PETERS, S ;
MARTIN, M ;
MARTIN, A ;
SOBEL, D ;
JONES, R ;
LARKIN, L ;
RICHERT, JR .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1994, 13 (01) :34-38